MDT Medtronic plc
USHealthcareAs of 2026-07-08 16:00
Why MDT matters now
Medtronic plc (MDT) is a US stock in Healthcare. The latest InvestLog snapshot shows $82.01 with -2.17% on the session and $104.98B in market capitalization; recent performance reads 1-month +0.97% and YTD -17.41%.
The latest financial table shown here is Q4 2026, with revenue of $9.81B, net income of $1.24B, and EPS of $0.96. Investors can compare that operating picture with valuation signals such as P/E 24.05 and FCF yield 5.3%.
The latest indexable market news headline is "Medtronic: A Near Decade High Dividend For This Aristocrat" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Hold with a median target of $90.00; recent insider activity includes KIIL HARRY SKIP filing S-Sale; recent congressional disclosure data includes Gilbert Cisneros Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
24.05
PEG
2.89
P/B
2.06
P/S
2.80
EV/EBITDA
13.16
DCF Value
$201.71
FCF Yield
5.3%
Div Yield
3.6%
Margins & Returns
Gross Margin
65.0%
Operating Margin
17.8%
Net Margin
13.2%
ROE
9.8%
ROA
5.2%
ROIC
6.1%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2026 | $9.81B | $1.24B | $0.96 |
| FY 2026 | $36.36B | $4.80B | $3.73 |
| Q3 2026 | $9.02B | $1.14B | $0.89 |
| Q2 2026 | $8.96B | $1.37B | $1.07 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$95.80
Target (Median)
$90.00
Target Range
$80.00 - $119.00
Trading Activity
Insider Trades
Congress Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
—
Beta
0.60
Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.